Summary:
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Effect of Vaccine Antibody Response in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD).
Qualified Participants Must:
• Be 18 years of age
•
Diagnosed with Atopic Dermatitis for at least 6 months
•
Have at least 7% of their body affected by the condition
Qualified Participants May Receive:
- Up to $3300
- Free medication
- free lab work